145 related articles for article (PubMed ID: 37366303)
1. Scaffold-based spheroid models of glioblastoma multiforme and its use in drug screening.
Manikandan C; Jaiswal AK
Biotechnol Bioeng; 2023 Aug; 120(8):2117-2132. PubMed ID: 37366303
[TBL] [Abstract][Full Text] [Related]
2. Hydrogel matrix presence and composition influence drug responses of encapsulated glioblastoma spheroids.
Hill L; Bruns J; Zustiak SP
Acta Biomater; 2021 Sep; 132():437-447. PubMed ID: 34010694
[TBL] [Abstract][Full Text] [Related]
3. Hydrogel-Based Spheroid Models of Glioblastoma for Drug Screening Applications.
Bruns J; Zustiak SP
Mo Med; 2021; 118(4):346-351. PubMed ID: 34373670
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Bruns J; Egan T; Mercier P; Zustiak SP
Acta Biomater; 2023 Jun; 163():400-414. PubMed ID: 35659918
[TBL] [Abstract][Full Text] [Related]
5. Drug Screening of Human GBM Spheroids in Brain Cancer Chip.
Akay M; Hite J; Avci NG; Fan Y; Akay Y; Lu G; Zhu JJ
Sci Rep; 2018 Oct; 8(1):15423. PubMed ID: 30337660
[TBL] [Abstract][Full Text] [Related]
6. The role of melatonin in angio-miR-associated inhibition of tumorigenesis and invasion in human glioblastoma tumour spheroids.
Doğanlar O; Doğanlar ZB; Delen E; Doğan A
Tissue Cell; 2021 Dec; 73():101617. PubMed ID: 34418770
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
8. Type-I Collagen/Collagenase Modulates the 3D Structure and Behavior of Glioblastoma Spheroid Models.
Calori IR; Alves SR; Bi H; Tedesco AC
ACS Appl Bio Mater; 2022 Feb; 5(2):723-733. PubMed ID: 35068151
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels.
Wang C; Tong X; Yang F
Mol Pharm; 2014 Jul; 11(7):2115-25. PubMed ID: 24712441
[TBL] [Abstract][Full Text] [Related]
10. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
11. The impact of temozolomide and lonafarnib on the stemness marker expression of glioblastoma cells in multicellular spheroids.
Nakod PS; Kondapaneni RV; Edney B; Kim Y; Rao SS
Biotechnol Prog; 2022 Sep; 38(5):e3284. PubMed ID: 35768943
[TBL] [Abstract][Full Text] [Related]
12. Advances in 3D culture systems for therapeutic discovery and development in brain cancer.
Wanigasekara J; Cullen PJ; Bourke P; Tiwari B; Curtin JF
Drug Discov Today; 2023 Feb; 28(2):103426. PubMed ID: 36332834
[TBL] [Abstract][Full Text] [Related]
13. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
Zhang X; Ding K; Wang J; Li X; Zhao P
Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
15. Engineered 3D tumour model for study of glioblastoma aggressiveness and drug evaluation on a detachably assembled microfluidic device.
Ma J; Li N; Wang Y; Wang L; Wei W; Shen L; Sun Y; Jiao Y; Chen W; Liu J
Biomed Microdevices; 2018 Sep; 20(3):80. PubMed ID: 30191323
[TBL] [Abstract][Full Text] [Related]
16. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Liu YC; Lee IC; Chen PY
J Neurooncol; 2018 May; 137(3):511-522. PubMed ID: 29357090
[TBL] [Abstract][Full Text] [Related]
17. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Bikhezar F; de Kruijff RM; van der Meer AJGM; Torrelo Villa G; van der Pol SMA; Becerril Aragon G; Gasol Garcia A; Narayan RS; de Vries HE; Slotman BJ; Denkova AG; Sminia P
J Neurooncol; 2020 Jan; 146(2):239-246. PubMed ID: 31875307
[TBL] [Abstract][Full Text] [Related]
20. Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy.
Wilson KM; Mathews-Griner LA; Williamson T; Guha R; Chen L; Shinn P; McKnight C; Michael S; Klumpp-Thomas C; Binder ZA; Ferrer M; Gallia GL; Thomas CJ; Riggins GJ
SLAS Technol; 2019 Feb; 24(1):28-40. PubMed ID: 30289729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
